This webinar will explore the intricate landscape of Alzheimer’s disease diagnosis and biomarkers, including, an examination of qualitative and quantitative diagnosis methods, an exploration of the challenges obstructing early detection, and a discussion of the imperative for non-invasive and cost-effective biomarkers.
Moreover, it will delve into the disparities in blood-based Amyloid and Tau biomarkers among different ethnic groups.
By the end of this session, participants will have gained valuable insights into the current state and future directions of Alzheimer’s disease diagnosis and biomarker research.
Date: Tuesday, 19 December 2023
Time: 17:00 CET / 11:00 ET
This activity is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): www.uems.eu
The webinar is designated for a maximum of, or up to, 1.5 European CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Dr. Fanny Elahi, Assistant Professor at the Icahn School of Medicine at Mount Sinai (USA)
Prof. Michelle M. Mielke, Chair, Department of Epidemiology and Prevention, Professor of Epidemiology and Prevention, Wake Forest University School of Medicine (USA)
Dr. Tamara Shiner, Specialist in Neurology, Tel Aviv Sourasky Medical Center (Israel)
Prof. Michael W. Weiner, Professor at the University of California San Francisco and Principal investigator of the Alzheimer’s Disease Neuroimaging Initiative (USA)
Dr. Marit Ruitenberg, Assistant Professor at the Health, Medical and Neuropsychology section at Leiden University (The Netherlands)
After the session, attendees will be given the tools to:
- Understand the landscape of Alzheimer’s disease diagnosis methods, covering both qualitative and quantitative approaches.
- Identify the key challenges that hinder early detection of Alzheimer’s disease.
- Gain knowledge on the importance of non-invasive and cost-effective biomarkers for Alzheimer’s disease diagnosis.
- Examine the disparities in blood-based Amyloid and Tau biomarkers across various ethnic groups.
- Grasp the current state and future directions in Alzheimer’s disease diagnosis and biomarker research.
This webinar is made possible through an unrestricted educational sponsorship from Novo Nordisk.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.
This educational activity is intended for an international audience of non-US and non-UK Healthcare Professionals.